INO-5150 in early treatment of biochemically recurrent prostate cancer

In 2015, Inovio Pharmaceuticals started a Phase I trial of INO-5150 — a new type of immunotherapy using a DNA vaccine for prostate cancer which targets both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA). … READ MORE …

New form of vaccine therapy — for low-risk prostate cancer

According to a media report on the MarketWatch web site, a company called OncBioMune is to initiate Phase II clinical trials of a new type of prostate cancer vaccine (ProscaVax). … READ MORE …

New prostate cancer vaccine makes it through Phase Ia trial

A company called OncBioMune Pharmaceuticals has announced initial data from a Phase Ia/Ib clinical trial of a new form of vaccine in the treatment of men with progressive prostate cancer who meet the following criteria: … READ MORE …

Prostvac-type vaccine therapy in progressive prostate cancer after first-line therapy

A study just published in European Urology has suggested that early therapy with Prostvac-type vaccines might have value in the management of men with a rising PSA after first-line therapy. … READ MORE …

CureVac starts Phase IIb trial of CV9104

A German company called CureVac GmbH has started Phase IIb clinical trials of another cancer “vaccine” for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Is possible new prostate cancer vaccine really “promising”?

A new article on the Medscape Oncology web site (and again correlated with a media release sent out by the European Association for Urology [EAU] from their annual meeting in Milan, Italy) is headed “Prostate cancer vaccine shows promise.” However, the degree of that “promise” appears to be open to some question. … READ MORE …

University of Iowa starts Phase II trials with Ad/PSA vaccine

A research team at the University of Iowa is seeking patients to enroll in Phase II clinical trials of a new form of vaccine immunotherapeutic to treat men with recurrent prostate cancer. … READ MORE …